Matrix metalloproteinase inhibition protects against junctophilin‐2 proteolysis during doxorubicin‐induced cardiotoxicity
These results reveal that JPH-2 proteolysis is a consequence of MMP-2 activation and highlight the beneficial prophylactic action of two orally available MMP inhibitors in preventing doxorubicin-induced cardiotoxicity.
Authors
- Wesam Bassiouni (ORCID: https://orcid.org/0000-0001-8410-3960)
- Andrej Roczkowsky (ORCID: https://orcid.org/0000-0001-6594-3016)
- John M. Seubert (ORCID: https://orcid.org/0000-0003-0764-3933)
- Howard S. Young (ORCID: https://orcid.org/0000-0002-5990-8422)
- Brandon Chan (ORCID: https://orcid.org/0000-0002-0924-017X)
- Zabed Mahmud (ORCID: https://orcid.org/0000-0001-5336-9002)
- Richard Schulz (ORCID: https://orcid.org/0000-0002-3365-8154)
- Joshua W. Kranrod (ORCID: https://orcid.org/0000-0001-8596-3153)
- Woo Jung Cho (ORCID: https://orcid.org/0000-0001-9837-0840)
- Joseph O. Primeau (ORCID: https://orcid.org/0000-0001-9734-3736)
Institutions
- St. Jude Children's Research Hospital (US)
- University of Alberta (CA)
- Alexion Pharmaceuticals (United States) (US)
- AstraZeneca (United States) (US)
- Imaging Center (US)
- Alexandria University (EG)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-05-15
- DOI
- https://doi.org/10.1111/bph.70047
- Citations
- 1
- Primary Topic
- Protease and Inhibitor Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- Heart and Stroke Foundation of Canada
- Alberta Innovates
- Canadian Institutes of Health Research